HALO Stock Analysis: Halozyme Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 8.891m USD | 12M Return: 50.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 127M
EPS Trend: 87.8%
Qual. Beats: 0
Rev. Trend: 98.5%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 10.5 years of data
Average return per month, with how dependable it is below — did the month move the same way every year (high) or randomly (low). Above 60 is a pattern worth trusting; under 40 is noise.
Halozyme Therapeutics is a San Diego-based biopharmaceutical company founded in 1998 that develops and commercializes proprietary enzyme technology, primarily its patented recombinant human hyaluronidase enzyme (rHuPH20). This platform enables the subcutaneous (SC) delivery of biologics and other therapeutics that are typically administered intravenously. The company sells its own products such as Hylenex recombinant and XYOSTED (testosterone replacement therapy) while generating significant revenue through licensing its ENHANZE technology to major pharmaceutical partners including Roche, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol Myers Squibb, Takeda, and argenx. Through these collaborations, rHuPH20 is incorporated into approved partner products such as Herceptin Hylecta, Phesgo, Mabthera SC, Tecentriq SC, Ocrevus SC, HYQVIA, and DARZALEX, spanning indications in oncology, immunology, and neurology. The company operates in the United States, Switzerland, Belgium, Japan, and other international markets.
As a biotechnology company in the Health Care sector, Halozyme operates a hybrid business model combining proprietary product sales with a platform-licensing structure, earning upfront payments, milestone fees, and royalties tied to partner product sales. Its core value proposition is converting intravenous biologics into SC formulations, which can reduce administration time, ease healthcare provider burden, and improve patient convenience compared to traditional IV infusions.
- DARZALEX subcutaneous franchise drives double-digit royalty revenue growth
- New ENHANZE partnership deals with argenx and others expand royalty pipeline
- rHuPH20 patent litigation outcomes pose key long-term stock overhang
| Net Income: 348.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.25 > 0.02 and ΔFCF/TA 2.41 > 1.0 |
| NWC/Revenue: 42.42% < 20% (prev 102.5%; Δ -60.11% < -1%) |
| CFO/TA 0.25 > 3% & CFO 677.4m > Net Income 348.8m |
| Net Debt (1.83b) to EBITDA (623.8m): 2.93 < 3 |
| Current Ratio: 2.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (122.9m) vs 12m ago -2.98% < -2% |
| Gross Margin: 76.93% > 18% (prev 80.17%; Δ -3.24% > 0.5%) |
| Asset Turnover: 61.96% > 50% (prev 49.36%; Δ 12.59% > 0%) |
| Interest Coverage Ratio: 27.34 > 6 (EBIT TTM 522.5m / Interest Expense TTM 19.1m) |
| A: 0.24 (Total Current Assets 1.00b - Total Current Liabilities 363.2m) / Total Assets 2.67b |
| B: 0.08 (Retained Earnings 204.8m / Total Assets 2.67b) |
| C: 0.21 (EBIT TTM 522.5m / Avg Total Assets 2.43b) |
| D: 0.09 (Book Value of Equity 219.6m / Total Liabilities 2.45b) |
| Altman-Z'' = 3.36 = A |
| DSRI: 1.08 (Receivables 458.0m/304.6m, Revenue 1.51b/1.08b) |
| GMI: 1.04 (GM 80.17% / 76.93%) |
| AQI: 1.51 (AQ_t 0.59 / AQ_t-1 0.39) |
| SGI: 1.39 (Revenue 1.51b / 1.08b) |
| TATA: -0.12 (NI 348.8m - CFO 677.4m) / TA 2.67b) |
| Beneish M = -2.35 (Cap -4..+1) = BBB |
As of July 01, 2026, the stock is trading at USD 78.27 with a total of 1,651,618 shares traded. Over the past week, the price has changed by +12.42%, over one month by +14.87%, over three months by +21.10% and over the past year by +50.46%.
Current recommended Stop Loss: 75.40 (which is 3.7% or 1.2 ATR below the current price).
Halozyme Therapeutics has received a consensus analysts rating of 3.63. Therefore, it is recommended to hold HALO.
- StrongBuy: 2
- Buy: 2
- Hold: 3
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 83.9 | 7.2% |
P/E Trailing = 26.3018
P/E Forward = 10.3842
P/S = 5.8943
P/B = 40.4817
P/EG = -2.5
Revenue TTM = 1.51b USD
EBIT TTM = 522.5m USD
EBITDA TTM = 623.8m USD
Long Term Debt = 1.94b USD (from longTermDebt, last quarter)
Short Term Debt = 208.7m USD (from shortTermDebt, last quarter)
Debt = 2.15b USD (from shortLongTermDebtTotal, last quarter) + Leases 2.55m
Net Debt = 1.83b USD (calculated: Debt 2.15b - CCE 318.6m)
Enterprise Value = 10.7b USD (8.89b + Debt 2.15b - CCE 318.6m)
Interest Coverage Ratio = 27.34 (Ebit TTM 522.5m / Interest Expense TTM 19.1m)
EV/FCF = 16.06x (Enterprise Value 10.7b / FCF TTM 667.7m)
FCF Yield = 6.23% (FCF TTM 667.7m / Enterprise Value 10.7b)
FCF Margin = 44.26% (FCF TTM 667.7m / Revenue TTM 1.51b)
Net Margin = 23.13% (Net Income TTM 348.8m / Revenue TTM 1.51b)
Gross Margin = 76.93% ((Revenue TTM 1.51b - Cost of Revenue TTM 348.0m) / Revenue TTM)
Gross Margin QoQ = 71.13% (prev 77.39%)
Tobins Q-Ratio = 4.01 (Enterprise Value 10.7b / Total Assets 2.67b)
Interest Expense / Debt = 0.89% (Interest Expense 19.1m / Debt 2.15b)
Taxrate = 30.70% (154.5m / 503.4m)
NOPAT = 362.1m (EBIT 522.5m * (1 - 30.70%))
Current Ratio = 2.76 (Total Current Assets 1.00b / Total Current Liabilities 363.2m)
Debt / Equity = 9.78 (Debt 2.15b / totalStockholderEquity, last quarter 219.6m)
Debt / EBITDA = 2.93 (Net Debt 1.83b / EBITDA 623.8m)
Debt / FCF = 2.74 (Net Debt 1.83b / FCF TTM 667.7m)
Total Stockholder Equity = 276.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 14.33% (Net Income 348.8m / Total Assets 2.67b)
RoE = 126.3% (Net Income TTM 348.8m / Total Stockholder Equity 276.3m)
RoCE = 23.62% (EBIT 522.5m / Capital Employed (Equity 276.3m + L.T.Debt 1.94b))
RoIC = 14.82% (NOPAT 362.1m / Invested Capital 2.44b)
WACC = 5.43% (E(8.89b)/V(11.0b) * Re(6.59%) + D(2.15b)/V(11.0b) * Rd(0.89%) * (1-Tc(0.31)))
Discount Rate = 6.59% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -68.89 | Cagr: -2.82%
[DCF] Terminal Value 77.97% ; FCFF base≈598.9m ; Y1≈686.5m ; Y5≈1.01b
[DCF] Fair Price = 112.8 (EV 15.2b - Net Debt 1.83b = Equity 13.4b / Shares 118.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 87.81 | EPS CAGR: 31.30% | SUE: -0.58 | # QB: 0
Revenue Correlation: 98.51 | Revenue CAGR: 28.07% | SUE: 1.07 | # QB: 1
EPS next Quarter (2026-09-30): EPS=2.18 | Chg30d=-0.24% | Revisions=-11% | Analysts=6
EPS current Year (2026-12-31): EPS=8.14 | Chg30d=+0.04% | Revisions=+25% | GrowthEPS=+96.2% | GrowthRev=+27.3%
EPS next Year (2027-12-31): EPS=9.89 | Chg30d=+0.59% | Revisions=+25% | GrowthEPS=+21.5% | GrowthRev=+12.5%
[Analyst] Revisions Ratio: +25%